PRRT Resources
CLINICAL TRIALS
EDUCATIONAL WEBINARS
LACNETS Educational Event
January 11, 2024
Join us on Thursday, January 11th at 9:30 AM Pacific to learn the latest on PRRT with NET expert Dr. Jonathan Strosberg. Dr. Strosberg was the principal investigator of the NETTER-1 study which led to the FDA approval of Lutathera and has authored numerous articles on PRRT. He will discuss the latest in PRRT, including special considerations and current clinical trials.
Watch "The Latest in PRRT" with Dr. Carina Mari Aparici. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023.
Nuclear Medicine Physician and Theranostics Director at Fred Hutchinson Cancer Center, Dr. Amir Iravani, shares the latest on Peptide Receptor Radionuclide Therapy (PRRT). Better understand the difference between beta and alpha PRRT, current trials and updates on PRRT for Lung NET, adolescents and dosimetry.
NET expert and radiologist Dr. Thomas Hope of UCSF addresses the latest in NET imaging and PRRT.
Nuclear Medicine Physician Dr. Erik Mittra provides an update on PRRT. Plus, hear from a NET patient who has received multiple rounds of PRRT treatments.
Nuclear medicine specialist Dr. Delpassand provides an update on the exciting advances in NET Management including Cu64 DOTATATE & Alpha PRRT.
READ
-
New Article: Sequencing of Somatostatin-Receptor–Based Therapies in Neuroendocrine Tumor Patients
-
This is an excellent review article giving a thorough overview of the evidence behind somatostatin receptor targeted therapies, which includes long-acting somatostatin analogues (SSAs) octreotide LAR and lanreotide, and radiolabeled SSAs, otherwise known as PRRT. The article offers insights regarding optimal patient selection, assessment of benefit versus risk, and treatment sequencing.
-
PRRT PATIENT/CAREGIVER STORIES
PRRT Patient/Caregiver Stories
PODCAST
%20(1).png)
%20(2).png)
%20(1).png)
.png)
PRRT CLINICAL TRIALS
COMPOSE is an international phase III clinical study to evaluate the efficacy, safety and impact on quality of life of Targeted Radionuclide Therapy (PRRT) with no-carrier-added lutetium-177-edotreotide (n.c.a. 177Lu-edotreotide) compared to a standard therapy with either CAPTEM or everolimus or FOLFOX, in patients with well-differentiated advanced Grade 2 and Grade 3, somatostatin receptor-positive (SSTR+) neuroendocrine tumors of gastroenteric or pancreatic origin (G2 and G3 GEP-NETs).
The study is being conducted predominantly in Europe, North America, India and Australia, in approximately 10 countries and 40 sites. Learn more and join the study here.
ALPHA PRRT PHASE 1B/3 TRIAL - GRADE 1-2 GEP-NETS WITH PROGRESSION AFTER PREVIOUS LUTATHERA TREATMENT
RayzeBio is sponsoring the ACTION-1 study, a phase 1b/3 open-label study of 225Ac-DOTATATE (RYZ101) compared with standard of care therapy in patients with inoperable, advanced, SSTR+ well-differentiated GEP-NET that has progressed following treatment with 177Lu-DOTATATE/TOC. The phase 3 portion is currently enrolling. More information on this trial can be found here.
This is not a comprehensive list of NET clinical trials. For more information about available clinical trials, go to www.clinicaltrials.gov.
NANETS NET GUIDELINES BY TOPIC
This is for informational use only. LACNETS is not endorsing or recommending any particular treatment or trials. LACNETS encourages you to discuss your individual needs and options with your medical team. For more information about available clinical trials, go to www.clinicaltrials.gov.